Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors
Canada NewsWire HAMILTON , ON and BOSTON , April 1, 2021 /CNW/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company
Read more
Pharma
Sierra Oncology Announces Momelotinib Data for Intermediate / High-risk Myelofibrosis Patients with Lower Baseline Platelet Counts
–Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count–
Read more
enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer
BOSTONand MONTRÉAL,Dec. 3, 2020/CNW Telbec/ – enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled
Read more
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies TOKYO, Nov 30, 2020 – (JCN
Read more
IPA Selects Polytope(TM) Formulations for Pre-Clinical Studies
Canada NewsWire VICTORIA, BC, Nov. 23, 2020 VICTORIA, BC,Nov. 23, 2020/CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE:
Read more